Fulcrum Therapeutics closed at $3.77 on Nov 4, up 0.80%, 74.2% below its 52-week closing high. Volume of 777.2K shares was 0.54× its 20-day average (below normal).
Split-adjusted performance: +2.2% over one month, -47.0% over six months, -58.2% over one year.
Short interest was 6.8M shares at the Oct 15 settlement, down 5.0% from the prior report (10.6% of float, 4.7 days to cover).
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD).
What is FULC's market cap?
$287.96M, based on the Nov 4 close of $3.77.
Does Fulcrum Therapeutics pay a dividend?
No regular cash dividend has been paid in the last year.
How much of FULC is sold short?
6.8M shares, 10.6% of float, as of Oct 15, 2026.
What sector is FULC in?
Healthcare, in the Pharmaceuticals industry.
About Fulcrum Therapeutics
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
